Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma
- PMID: 31553403
- PMCID: PMC6764120
- DOI: 10.1001/jamadermatol.2019.2890
Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma
Abstract
Importance: Melanoma is among the most common malignant neoplasms in the United States, with 91 270 cases estimated to be diagnosed in 2018. Since 2012, Mohs micrographic surgery (MMS) has gained popularity in the treatment of melanoma in situ. Although current guidelines for invasive melanoma without nodal metastases recommend surgery with wide margin excision (WME), use of MMS for this disease has increased as well, particularly in early stages. How the survival outcomes after each procedure compare with one another for early-stage invasive melanoma is unknown to date.
Objective: To evaluate overall survival of patients with stage I melanoma defined by the American Joint Committee on Cancer Cancer Staging Manual, 8th edition (AJCC-8) after MMS vs traditional WME.
Design, setting, and analysis: This retrospective cohort study includes all patients with AJCC-8 stage I melanoma who underwent MMS or WME in the National Cancer Database with a diagnosis from January 1, 2004, through December 31, 2014. The National Cancer Database includes all reportable cases from Commission on Cancer-accredited facilities and represents approximately 50% of all newly diagnosed melanoma cases in the United States. Data were analyzed from November 13, 2018, through June 9, 2019.
Exposures: MMS vs WME.
Main outcomes and measures: Overall survival evaluated using multivariable Cox proportional hazards regression analysis.
Results: A total of 70 319 eligible patients (52.3% male and 47.7% female; median [SD] age, 57.0 [16.2] years) were identified, including 67 085 treated with WME and 3234 treated with MMS. Multivariable Cox proportional hazards regression survival analysis controlling for clinical and tumor factors revealed that treatment with MMS was associated with a modest improvement in overall survival relative to WME (hazard ratio [HR], 0.86; 95% CI, 0.76-0.97). Propensity score-matched analysis of cohorts of patients treated with MMS vs WME also found modestly improved survival for those treated with MMS (HR, 0.82; 95% CI, 0.68-0.98). Academic facilities were more likely to use MMS than nonacademic facilities (odds ratio, 2.03; 95% CI, 1.88-2.18).
Conclusions and relevance: These findings suggest that Mohs surgery may provide an alternative approach to traditional WME for appropriately selected cases of AJCC-8 stage I melanoma without compromising patient survival.
Conflict of interest statement
Figures
Comment in
-
Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research.JAMA Dermatol. 2020 Sep 1;156(9):1028-1029. doi: 10.1001/jamadermatol.2020.1310. JAMA Dermatol. 2020. PMID: 32520342 No abstract available.
-
Clarification Regarding Noninferiority and a Discussion of Model Selection and Treatment Effects in Observational Research-Reply.JAMA Dermatol. 2020 Sep 1;156(9):1029. doi: 10.1001/jamadermatol.2020.0543. JAMA Dermatol. 2020. PMID: 32520348 No abstract available.
Similar articles
-
Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma.JAMA Dermatol. 2021 May 1;157(5):531-539. doi: 10.1001/jamadermatol.2021.0023. JAMA Dermatol. 2021. PMID: 33787836 Free PMC article.
-
Overall Survival After Mohs Surgery for Early-Stage Merkel Cell Carcinoma.JAMA Dermatol. 2023 Oct 1;159(10):1068-1075. doi: 10.1001/jamadermatol.2023.2822. JAMA Dermatol. 2023. PMID: 37610773
-
Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.JAMA Dermatol. 2017 May 1;153(5):436-441. doi: 10.1001/jamadermatol.2016.6138. JAMA Dermatol. 2017. PMID: 28241261 Free PMC article.
-
Mohs micrographic surgery in the surgical treatment paradigm of melanoma in situ and invasive melanoma: A clinical review of treatment efficacy and ongoing controversies.J Am Acad Dermatol. 2024 May 19:S0190-9622(24)00756-4. doi: 10.1016/j.jaad.2024.05.024. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38768857 Review.
-
Current perspectives on Mohs micrographic surgery for melanoma.Clin Cosmet Investig Dermatol. 2018 Jun 20;11:309-320. doi: 10.2147/CCID.S137513. eCollection 2018. Clin Cosmet Investig Dermatol. 2018. PMID: 29950878 Free PMC article. Review.
Cited by
-
Disease-specific survival of malignant melanoma after Mohs micrographic surgery is not impacted by initial margins: A systematic review and meta-analysis.JAAD Int. 2023 Jun 28;13:140-149. doi: 10.1016/j.jdin.2023.06.009. eCollection 2023 Dec. JAAD Int. 2023. PMID: 37823046 Free PMC article.
-
Development and validation of two online dynamic nomograms for patients with non-distant metastatic cutaneous melanoma based on surgical approaches.Cancer Med. 2023 Sep;12(18):18479-18490. doi: 10.1002/cam4.6448. Epub 2023 Aug 18. Cancer Med. 2023. PMID: 37592896 Free PMC article.
-
Increasing utilization of Mohs micrographic surgery for melanoma in the United States: A National Cancer Database analysis.JAAD Int. 2023 Feb 13;11:92-94. doi: 10.1016/j.jdin.2023.01.016. eCollection 2023 Jun. JAAD Int. 2023. PMID: 36941914 Free PMC article. No abstract available.
-
Mohs Micrographic Surgery for Melanoma: A Convincing Treatment Modality.Indian J Dermatol. 2022 Jul-Aug;67(4):479. doi: 10.4103/ijd.ijd_1074_20. Indian J Dermatol. 2022. PMID: 36578768 Free PMC article.
-
Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer.Cancers (Basel). 2022 Aug 8;14(15):3835. doi: 10.3390/cancers14153835. Cancers (Basel). 2022. PMID: 35954498 Free PMC article. Review.
References
-
- American Cancer Society Cancer Facts & Figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-.... Published January 2018. Accessed December 2018.
-
- National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology (NCCN guidelines): melanoma (version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Published March 12, 2019. Accessed July 9, 2018.
Grants and funding
LinkOut - more resources
Full Text Sources